Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Additional Locations, Maryland Clinical Trials

A listing of Additional Locations, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (16) clinical trials

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 ...

Phase

4.48 miles

Learn More »

Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of ...

Phase N/A

4.73 miles

Learn More »

A Study Assessing the Safety Tolerability and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.

Phase

6.72 miles

Learn More »

Umbilical Cord Milking in Non-Vigorous Infants

At birth, it is critical that an infant begins breathing quickly. The infant has to switch from relying on the placenta for oxygen to using its lungs for the first time. The currently recommended practice for infants who need resuscitation is to immediately clamp the umbilical cord. Animal studies show ...

Phase N/A

6.8 miles

Learn More »

An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.

Phase

7.31 miles

Learn More »

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).

Phase

7.31 miles

Learn More »

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Approximately 650 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study ...

Phase N/A

8.07 miles

Learn More »

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

PRIMARY OBJECTIVES: I. Determine the toxicities and maximum tolerated dose (MTD) of birinapant concurrent with intensity modulated re-irradiation therapy (IMRRT). SECONDARY OBJECTIVES: I. Determine the objective response rate of patients with locoregionally recurrent head and neck squamous cell carcinoma (HNSCC) treated with re-irradiation and birinapant. II. Determine the local-regional control, ...

Phase

8.17 miles

Learn More »

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Background BRCA1-Associated Protein-1 (BAP1), a deubiquitinase involved in regulating DNA repair enzymes, is believed to be a prominent mutation in malignant mesothelioma Germline mutations involving BAP1 have been reported in familial studies. These have been associated with a higher likelihood of mesothelioma as well as several other malignancies, including uveal ...

Phase N/A

8.17 miles

Learn More »

Mechanism of Action Underlying Ketamine s Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Objective Work by our group and others has demonstrated that a single intravenous dose of the glutamatergic modulator ketamine consistently produces rapid (within two hours), robust, and relatively sustained (approximately one to two weeks) antidepressant effects in patients with treatment-resistant major depressive disorder (MDD) and bipolar depression. Although ketamine is ...

Phase

8.17 miles

Learn More »